20-F: Pharvaris N.V. Files 20-F Annual Report, Outlines Financials and Development Pipeline

Pharvaris N.V. files its annual report, detailing its financial status and progress in developing innovative therapies for rare diseases, particularly angioedema.

Summary

• Pharvaris N.V., a biopharmaceutical company, has filed its annual report on Form 20-F.
• The company is focused on developing therapies for rare diseases, particularly angioedema.
• The lead product candidate is deucrictibant, an oral bradykinin B2 receptor antagonist.
• Deucrictibant has two formulations: an immediate-release (IR) capsule for acute attacks and an extended-release (XR) tablet for prophylaxis.
• Phase 2 trials (RAPIDe-1 and CHAPTER-1) have shown efficacy for both formulations.
• The FDA previously placed clinical holds on deucrictibant trials, but these have been lifted.
• Phase 3 trials (RAPIDe-3 and CHAPTER-3) are underway to further evaluate the efficacy and safety of deucrictibant.
• The company reported a net loss of 134.2 million for the year ended December 31, 2024.
• As of December 31, 2024, the company had cash and cash equivalents of 280.7 million.
• The company expects to incur increasing research and development expenses in the future.
• The company is subject to various risks, including clinical trial setbacks, regulatory hurdles, and competition.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's progress in clinical trials and a strong cash position, the increasing losses and inherent risks in drug development temper the overall outlook.

Positives

• Phase 2 trials have demonstrated efficacy for both the IR and XR formulations of deucrictibant.
• The FDA clinical holds on deucrictibant trials have been lifted.
• Phase 3 trials are underway, indicating progress towards potential regulatory approval.
• The company has a significant cash balance of 280.7 million as of December 31, 2024.

Negatives

• The company reported a net loss of 134.2 million for the year ended December 31, 2024.
• The company expects to incur increasing research and development expenses in the future.

Risks

• Clinical trials may experience setbacks or fail to demonstrate desired efficacy or safety.
• Regulatory approvals may be delayed or denied.
• The company faces competition from existing therapies and emerging competitors.
• Manufacturing issues may arise, increasing costs or delaying commercialization.
• The market opportunities for product candidates may be smaller than anticipated.
• The company may be exposed to liability claims.
• The company relies on third parties for critical activities.
• The company may be unable to obtain or maintain patent protection.
• The market price of the company's ordinary shares is likely to be highly volatile.
• The company may be a passive foreign investment company (PFIC), which could result in adverse U.S. federal income tax consequences to U.S. investors.

Future Outlook

The company expects to incur increasing research and development expenses as it continues to develop its product candidates and explore potential expansion programs.

Industry Context

The global market for HAE treatments is estimated at approximately $2.7 billion in 2022 and is forecast to grow to $4.3 billion by 2027.

Comparison to Industry Standards

• The document mentions FIRAZYR (icatibant) as a bradykinin B2 receptor antagonist approved for acute HAE attacks, highlighting deucrictibant's potential to improve upon its therapeutic profile.
• TAKHZYRO (lanadelumab-flyo) is mentioned as a monoclonal antibody approved for prophylaxis of HAE attacks, providing context for Pharvaris's XR tablet development.
• ORLADEYO (berotralstat) is noted as an orally administered kallikrein inhibitor for HAE prevention, setting a benchmark for Pharvaris's oral therapy approach.
• Kalvista's sebetralstat (KVD900) is mentioned as another oral therapy in development for acute HAE treatment, indicating the competitive landscape.

Related Party Transactions

• The Company engages GrayMatters, a management entity for the purpose of providing key management services to the Company. This management entity is considered a related party, as it provides key management services and exercises key management functions.
• In June 2023, the Company entered into a subscription agreement dated June 16, 2023 relating to the offer and sale of an aggregate of 6,951,340 ordinary shares of the Company, in a private placement to a group of institutional investors, led by General Atlantic and venBio Partners with participation from Bain Capital Life Sciences, Foresite Capital, and Venrock Healthcare Capital Partners, at an offering price of $10.07 per share, for gross proceeds of approximately $70 million before deducting any offering-related expenses.
• In December 2023, the Company entered into an underwriting agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC as underwriters, pursuant to which the Company agreed to issue and sell (i) 11,125,000 ordinary shares, par value 0.12 per share and (ii) pre-funded warrants to purchase up to 1,375,000 ordinary shares in an underwritten offering.
• On February 5, 2024, the Company entered into a registration rights agreement (the GA Registration Rights Agreement) with General Atlantic PH B.V. relating to the exercised pre-funded warrants to purchase up to 1,375,000 ordinary shares of the Company, which pre-funded warrants were acquired by General Atlantic PH B.V. in December 2023.

Stakeholder Impact

• Shareholders: The company's financial performance and development pipeline directly impact shareholder value.
• Patients: The development of new therapies for rare diseases, particularly angioedema, has the potential to improve patient outcomes and quality of life.
• Employees: The company's growth and development activities impact employment opportunities and job security.
• Creditors: The company's financial stability and ability to meet its obligations are important to creditors.
• Suppliers: The company's research and development activities and manufacturing plans impact its relationships with suppliers.

Next Steps

• Continue to advance deucrictibant through clinical development for on-demand treatment of HAE utilizing a rapid-onset formulation, known as deucrictibant immediate-release (IR) capsules.
• Advance the development of deucrictibant for prophylactic treatment of HAE utilizing an extended-release formulation, known as deucrictibant extended-release (XR) tablets.
• Expand the range of bradykinin-mediated angioedema indications to which deucrictibant can be applied.
• Expand upon our expertise in the bradykinin B2 receptor pathway.
• Commercialize our product candidates.

Key Dates

Keywords

deucrictibant, hereditary angioedema, HAE, clinical trials, pharmaceutical, bradykinin, FDA, rare diseases, biopharmaceutical, angioedema